HIV
Cambodia has made significant strides in its HIV response by becoming the first country in Asia and the Pacific to integrate both CAB-LA (long-acting injectable PrEP) and the dapivirine vaginal ring into its public health system. This historic move marks a major advancement in HIV prevention for women, offering a
HIV
Internalized HIV stigma remains a significant barrier for individuals living with HIV, leading to negative consequences for their mental and physical health. A recent preprint study describes the design, implementation, and evaluation of RESET, a face-to-face intervention program aimed at reducing internalized HIV stigma among people with HIV in the
Highly active antiretroviral therapy
The Gates Foundation has partnered with Hetero, a global leader in APIs and generic drug manufacturing, to supply a generic version of lenacapavir for HIV prevention. This collaboration aims to make a low-cost, twice-yearly injectable PrEP therapy accessible to millions of people at risk of HIV in low- and middle-income
Health policy
Investigations into the factors driving HIV diagnoses in the US have shed light on the significant role that Social Determinants of Health (SDoH) play in the sustained diagnosis rate. Contrary to expectations, the rate of HIV diagnoses has remained steady over the past decade, despite the availability of condoms and
Depression (Mood disorder)
Researchers at Link Campus University in Rome, Italy have found that despite medical advances, stigma remains a significant challenge for individuals living with HIV (PLWH). The study aimed to examine clinical, sociodemographic, and psychological predictors of HIV-related stigma, and explored whether affective temperament moderates the impact of depression on stigma.
AIDS vaccines
The World Health Organisation (WHO) has made a significant endorsement for the use of injectable lenacapavir, administered twice yearly, to provide near-total protection against HIV infection. This breakthrough was announced during the 13th International AIDS Society (IAS 2025) Conference on HIV Science in Kigali, Rwanda, where the new WHO guidelines
HIV
As South Africa prepares to roll out the HIV prevention jab, lenacapavir, scientists and policymakers warn that the country's limited funds and health system capacity may hinder the ambitious plan to put two to four million people on the medication per year. The Global Fund has offered a
AIDS treatment
A new analysis has revealed that lenacapavir, a long-acting injectable for HIV prevention, could be produced for as little as $25 per person per year, potentially transforming global efforts to end the HIV epidemic. The study, co-authored by Andrew Hill and featured in The Lancet, demonstrates that generic production costs
Gilead Sciences Inc.
Washington-based non-profit medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) is sounding the alarm over the limited access to the HIV prevention medicine lenacapavir, partly due to restrictive patent licensing agreements imposed by the developer, Gilead Sciences. The organization welcomes the World Health Organization's (WHO) recommendation
Evidence-based medicine
The World Health Organization (WHO) has released new guidelines recommending the use of injectable lenacapavir (LEN) as an additional pre-exposure prophylaxis (PrEP) option for HIV prevention, alongside daily oral pills and other shorter-acting options. LEN, the first twice-yearly injectable PrEP product, offers a highly effective, long-acting alternative that can be
HIV
The Global Fund to Fight AIDS, Tuberculosis and Malaria has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries. This historic agreement marks the first time an HIV prevention product will be introduced in low- and middle-income countries
HIV
The Global Fund to Fight AIDS, Tuberculosis and Malaria has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable for HIV prevention, for low- and middle-income countries (LMICs). This marks the first time an HIV prevention product will be introduced in LMICs simultaneously with high-income countries,
